Study on the Prognostic Value of Aberrant Antigen in Patients With Acute B Lymphocytic Leukemia.

Authors:
Dr. Jun Liu, PhD
Dr. Jun Liu, PhD
The University of Texas at Austin
Postdoctoral Fellow
ITS, Safety, Engery
Austin, Texas | United States
Xu Tan
Xu Tan
Institute of Combined Injury
China
Yao Liu
Yao Liu
Southwest Hospital
Oklahoma City | United States
Li Gao
Li Gao
Nanjing Medical University
China
Lei Gao
Lei Gao
School of Public Health
New Haven | United States

Clin Lymphoma Myeloma Leuk 2019 Mar 25. Epub 2019 Mar 25.

Department of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, People's Republic of China. Electronic address:

Background: Approximately 30% to 60% of patients with acute B-lymphocytic leukemia (B-ALL) show as refractory or relapsed, which is one of the major causes of death in patients with B-ALL, but the methods of the treatment for relapsed/refractory B-ALL (R/R B-ALL) are limited. The chimeric antigen receptors redirected T cells (CAR-T cells) have showed a strong anti-leukemia role for B-ALL. About 90% of patients with R/R B-ALL treated with CD19-CAR-T cells achieved complete remission. However, 60% to 70% of patients relapsed after CAR-T cells treatment, which may be related to target antigen reduction or escape. New products are urgently needed to prevent and treat antigenic escapes causing recurrence.

Patients And Methods: In this article, we retrospectively analyzed the immunophenotype of patients with B-ALL initially diagnosed in our center from January 2010 to December 2015 to determine whether aberrant antigen expression was associated with the prognosis of patients in order to find new targets for immunotherapy.

Results: The results show that disease-free and overall survival in patients without aberrant antigen expression were better than patients with aberrant antigen expression. The most common abnormal antigens were CD123, CD13, and CD56. Correlation analysis showed a negative correlation between aberrant CD123 expression and both disease-free and overall survival.

Conclusion: Therefore, in the construction of CAR-T cells in patients with R/R B-ALL, conventional CD19 can be combined with aberrant antigens such as CD123 to form CARs with bi-specific antigens or multi-specific antigens may achieve the purpose of improving efficacy. However, more clinical trials are needed.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.03.012DOI Listing
March 2019
1 Read

Publication Analysis

Top Keywords

aberrant antigen
16
car-t cells
12
r/r b-all
12
antigen expression
12
patients
10
b-all
8
antigens cd123
8
patients aberrant
8
patients acute
8
patients r/r
8
patients b-all
8
aberrant
6
antigen
6
cells
5
escapes causing
4
antigenic escapes
4
treat antigenic
4
cells patients
4
methods article
4
disease-free survivalconclusion
4

Similar Publications